Similar bronchodilation with formoterol delivered by aerolizer or turbuhaler.

Autor: Lötvall J; Göteborg University, Sahlgrenska University Hospital, Göteborg, Sweden. jan.lotvall@mailer.mednet.gu.se, Mellén A, Arvidsson P, Palmqvist M, Radielovic P, Kottakis J, Pfister P
Jazyk: angličtina
Zdroj: Canadian respiratory journal [Can Respir J] 1999 Sep-Oct; Vol. 6 (5), pp. 412-6.
DOI: 10.1155/1999/193245
Abstrakt: Background: In many countries, two dry powder formulations of inhaled formoterol are available for clinical use; one uses a single-dose device (Foradil, Aerolizer), and the other uses a multiple-dose device (Oxis, Turbuhaler).
Objectives: To study the bronchodilating effect of formoterol 12 mg when delivered via the Aerolizer and Turbuhaler devices over 12 h.
Study Design: Randomized, double-blind, placebo controlled crossover study. Forced expiratory volume in one second (FEV1) was monitored during a 12 h period.
Patients: Nineteen nonsmoking asthma patients were included in the trial on the basis of reversibility of symptoms in response to inhaled salbutamol (either 200 or 400 mg given cumulatively; minimum reversibility 15%).
Results: There were no significant differences between the two dry powder devices regarding the change from baseline of FEV1 over 12 h, the area under the curve of FEV1 over 12 h or the maximum value of FEV1. The improvement in FEV1 with formoterol 12 mg versus placebo was highly significant for both devices.
Conclusions: Formoterol is similarly effective when used as a dry powder when given by either Aerolizer or the Turbuhaler.
Databáze: MEDLINE
Externí odkaz: